Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
BUR's Cash to Debt is ranked higher than
91% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. BUR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BUR' s 10-Year Cash to Debt Range
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.86
BUR's Equity to Asset is ranked higher than
74% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. BUR: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
BUR' s 10-Year Equity to Asset Range
Min: 0.84  Med: 0.86 Max: 0.93
Current: 0.86
0.84
0.93
F-Score: 4
Z-Score: 45.04
M-Score: -3.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6499.06
BUR's Operating margin (%) is ranked lower than
90% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. BUR: -6499.06 )
Ranked among companies with meaningful Operating margin (%) only.
BUR' s 10-Year Operating margin (%) Range
Min: -18770  Med: -6582.11 Max: -6560.95
Current: -6499.06
-18770
-6560.95
Net-margin (%) -6206.60
BUR's Net-margin (%) is ranked lower than
90% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. BUR: -6206.60 )
Ranked among companies with meaningful Net-margin (%) only.
BUR' s 10-Year Net-margin (%) Range
Min: -18486.67  Med: -6275.79 Max: -6265.71
Current: -6206.6
-18486.67
-6265.71
ROE (%) -109.34
BUR's ROE (%) is ranked lower than
83% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. BUR: -109.34 )
Ranked among companies with meaningful ROE (%) only.
BUR' s 10-Year ROE (%) Range
Min: -130.08  Med: -63.94 Max: -22.1
Current: -109.34
-130.08
-22.1
ROA (%) -97.12
BUR's ROA (%) is ranked lower than
86% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. BUR: -97.12 )
Ranked among companies with meaningful ROA (%) only.
BUR' s 10-Year ROA (%) Range
Min: -111.29  Med: -60.66 Max: -21.77
Current: -97.12
-111.29
-21.77
ROC (Joel Greenblatt) (%) -1070.54
BUR's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. BUR: -1070.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BUR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1207.15  Med: -628.66 Max: -167.13
Current: -1070.54
-1207.15
-167.13
EBITDA Growth (3Y)(%) -7.20
BUR's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. BUR: -7.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BUR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 49.4
Current: -7.2
0
49.4
» BUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BUR Guru Trades in Q1 2014

Chuck Royce 419,903 sh (unchged)
» More
Q2 2014

BUR Guru Trades in Q2 2014

Chuck Royce 433,253 sh (+3.18%)
» More
Q3 2014

BUR Guru Trades in Q3 2014

Chuck Royce 419,903 sh (-3.08%)
» More
Q4 2014

BUR Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 11.21
BUR's Forward P/E is ranked higher than
91% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. BUR: 11.21 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 17.09
BUR's P/B is ranked lower than
86% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BUR: 17.09 )
Ranked among companies with meaningful P/B only.
BUR' s 10-Year P/B Range
Min: 0  Med: 0.00 Max: 31.3
Current: 17.09
0
31.3
P/S 929.31
BUR's P/S is ranked lower than
180% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. BUR: 929.31 )
Ranked among companies with meaningful P/S only.
BUR' s 10-Year P/S Range
Min: 0  Med: 0.00 Max: 10747.6
Current: 929.31
0
10747.6
EV-to-EBIT -12.60
BUR's EV-to-EBIT is ranked lower than
475% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. BUR: -12.60 )
Ranked among companies with meaningful EV-to-EBIT only.
BUR' s 10-Year EV-to-EBIT Range
Min: 0  Med: 0.00 Max: 0
Current: -12.6
Current Ratio 4.44
BUR's Current Ratio is ranked higher than
51% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. BUR: 4.44 )
Ranked among companies with meaningful Current Ratio only.
BUR' s 10-Year Current Ratio Range
Min: 2.12  Med: 9.07 Max: 35.2
Current: 4.44
2.12
35.2
Quick Ratio 4.44
BUR's Quick Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BUR: 4.44 )
Ranked among companies with meaningful Quick Ratio only.
BUR' s 10-Year Quick Ratio Range
Min: 2.12  Med: 9.07 Max: 35.2
Current: 4.44
2.12
35.2
Days Sales Outstanding 502.74
BUR's Days Sales Outstanding is ranked lower than
98% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. BUR: 502.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
BUR' s 10-Year Days Sales Outstanding Range
Min: 425.83  Med: 507.52 Max: 541.74
Current: 502.74
425.83
541.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 37.50
BUR's Price/Net Cash is ranked lower than
83% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. BUR: 37.50 )
Ranked among companies with meaningful Price/Net Cash only.
BUR' s 10-Year Price/Net Cash Range
Min: 9.89  Med: 25.03 Max: 204.5
Current: 37.5
9.89
204.5
Price/Net Current Asset Value 37.50
BUR's Price/Net Current Asset Value is ranked lower than
84% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. BUR: 37.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BUR' s 10-Year Price/Net Current Asset Value Range
Min: 9.37  Med: 25.03 Max: 136.33
Current: 37.5
9.37
136.33
Price/Tangible Book 22.50
BUR's Price/Tangible Book is ranked lower than
87% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. BUR: 22.50 )
Ranked among companies with meaningful Price/Tangible Book only.
BUR' s 10-Year Price/Tangible Book Range
Min: 6.59  Med: 14.89 Max: 50
Current: 22.5
6.59
50
Earnings Yield (Greenblatt) (%) -7.92
BUR's Earnings Yield (Greenblatt) (%) is ranked lower than
57% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BUR: -7.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BUR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -9.2  Med: 0.00 Max: 0
Current: -7.92
-9.2
0

Analyst Estimate

Mar16 Mar17
EPS($) 0.19 0.75
EPS without NRI($) 0.19 0.75

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BU.Canada, BNE.Germany,
Burcon NutraScience Corp was incorporated on November 3, 1998. The Company, through its subsidiary, Burcon NutraScience (MB) Corp. is a research and development company building a portfolio of composition, application and process patents around its plant protein extraction and purification technology. The Company's products include CLARISOY, a soy protein isolate, which is used in various food products, including protein shakes, power bars, soups and sauces, meats and meat analogs, and breads and baked foods; and PEAZAZZ, a soluble pea protein isolate. Its products also comprise canola protein isolates, such as Supertein that comprises albumin proteins used in beverages, confectionery, aerated desserts, and protein bars; Puratein, which consists of globulin proteins used in dressings and sauces, meat substitutes, baked goods, and protein bars.
» More Articles for BUR

Headlines

Articles On GuruFocus.com
Burelle: A Growing Euro for 50 cents Mar 12 2013 

More From Other Websites
4th Annual Gateway Conference to Showcase More Than 80 Growth Companies in San Francisco on... Jul 21 2015
ACI Bolsters Board of Directors with New Appointments Jul 08 2015
Burcon Nutrascience (BUR) Looks Good: Stock Adds 6.6% - Tale of the Tape Jul 02 2015
BURCON NUTRASCIENCE CORP Financials Jun 27 2015
BURCON REPORTS FISCAL FOURTH QUARTER AND YEAR 2015 RESULTS Jun 23 2015
Burcon reports 4Q loss Jun 23 2015
Burcon reports 4Q loss Jun 23 2015
Burcon Reports Fiscal Fourth Quarter and Year 2015 Results Jun 23 2015
BURCON SETS FOURTH QUARTER AND FISCAL YEAR 2015 CONFERENCE CALL FOR JUNE 23, 2015 AT 5:00 P.M. ET Jun 15 2015
Burcon Sets Fourth Quarter and Fiscal Year 2015 Conference Call for June 23, 2015 at 5:00 p.m. ET Jun 15 2015
Burcon Nutrascience Corporation (BUR) Jumps, Stock Rises 7% - Tale of the Tape May 27 2015
Burcon Announces Completion of Over-Subscribed Rights Offering May 01 2015
BURCON TO PRESENT AT THE 14TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE ON APRIL 15, 2015 Apr 02 2015
BURCON TO PRESENT AT THE 27TH ANNUAL ROTH CONFERENCE ON MARCH 10, 2015 Mar 02 2015
Will Sysco Win Antitrust Lawsuit on US Foods Deal? - Analyst Blog Feb 23 2015
Burcon reports 3Q loss Feb 17 2015
Burcon reports 3Q loss Feb 17 2015
BURCON REPORTS FISCAL 2015 THIRD QUARTER RESULTS Feb 16 2015
Campbell Soup Falls on Weaker Sales and Profit Projections - Analyst Blog Feb 13 2015
J.M. Smucker Q3 Earnings Beat, Sales Miss as Volumes Fall - Analyst Blog Feb 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK